Neuroblastoma detected by novel biomarker assay with increased sensitivity

New research from The Saban Research Institute of Children’s Hospital Los Angeles (CHLA) (CA, US), has resulted in the development and testing of a novel biomarker assay that detects the presence of neuroblastoma as well as quantifying disease, even in cases where standard evaluations yield negative results. Published recently in Clinical Cancer Research, the study led by Araz Marachelian (CHLA), provides the first systemic comparison of conventional imaging evaluations against the new assay, which screens for five different neuroblastoma-associated genes; the study determined that the assay improves disease assessment as well as providing prediction of disease progression. A cancer of...